[시장보고서]세계의 혈전 치료 시장 예측(-2030년)

세계의 혈전 치료 시장 예측(-2030년)

Thrombus Treatment Market Forecast to 2030

상품코드 : 1312438 해당 상품은 즉시 배송 가능합니다

리서치사 : Market Research Future

발행일 : 2023년 07월

페이지 정보 : 영문 128 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,950

￦ 6,777,000

PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다.

US $ 5,950

￦ 8,146,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 기업 내 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다.

US $ 7,250

￦ 9,925,000

PDF & Excel (Enterprise License)

PDF, Excel 보고서를 동일 기업이 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능하며, 인쇄 가능합니다.

한글목차

세계의 혈전 치료 시장 규모는 예측 기간 중 CAGR로 6.84%의 성장이 예측됩니다.

세계의 혈전 치료 시장에 대해 조사분석했으며, 시장 역학, 지역과 부문 분석, 기업 개요 등을 제공하고 있습니다.

밸류체인 분석
- 연구개발
- 제조
- 유통·판매
- 판매 후 모니터링
Porter's Five Forces 모델
세계의 혈전 치료 시장에 대한 COVID-19의 영향
- 공급망에 대한 영향
- 생산에 대한 영향
- 수급 격차 분석
- 가격결정에 대한 영향
폐색전증의 시술 건수

제6장 세계의 혈전 치료 시장 : 유형별

개요
심방 혈전
정맥혈전

제7장 세계의 혈전 치료 시장 : 치료별

개요
약물치료
수술
기타

제8장 세계의 혈전 치료 시장 : 지역별

개요
- 북미
- 유럽
- 아시아태평양
- 기타 지역

제9장 경쟁 구도

개요
경쟁 벤치마킹
세계 혈전 치료 시장의 주요 성장 전략
세계의 혈전 치료 시장에서 개발 수의 주요 기업
주요 발전 분석
주요 발전과 성장 전략
- 제품 승인/제품 발매
- 파트너십/제휴
주요 기업의 재무 매트릭스
- 판매(2021년)
- 연구개발(2021년)

제10장 기업 개요

TEVA PHARMACEUTICAL INDUSTRIES LTD.
SANOFI
PFIZER INC.
BAYER AG
ANGIODYNAMICS.
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL-MYERS SQUIBB COMPANY
ASPEN HOLDINGS
JOHNSON & JOHNSON SERVICES, INC.
DAIICHI SANKYO COMPANY, LIMITED

제11장 부록

KSA

영문 목차

영문목차

Market Overview

The thrombus treatment market is projected to enroll a solid CAGR of 6.84% during the conjecture time frame. The elements impacting the market development are the rising rate of injury cases and the rising reception of a stationary way of life supporting the market development.

Injury is viewed as one of the most widely recognized reasons for the arrangement of thrombus in the lower limits. At the point when any veins get harmed, the encompassing blood thickens and frames a coagulation. Subsequently, vein harm because of injury can cause the development of a thrombus. The expanded number of injury cases, particularly street mishaps has prompted an expansion popular of thrombus treatment. As per the WHO in June2018, around 1.3 million individuals lose their lives because of street mishaps universally. Moreover, there were 178 million new break cases enlisted in 2019 worldwide which had expanded by 33.4% beginning around 1990. The absolute pervasiveness of intense and long-haul break side effects had reached 455 million of every 2910 with an increment of 67.5% starting around 1990. The break is one more typical reason for apoplexy. Consequently, the rising occurrence of injury cases is driving market interest in Thrombus Treatment.

Market Segmentation

Atrial and venous thrombus are the two market segments for thrombus treatment, respectively. Right atrial thrombus and left atrial thrombus were formed from the atrial thrombus.

Data on the thrombus treatment market has been divided into treatment categories such as medicinal therapy, surgery, and others. Thrombolytics, antiplatelets, and anticoagulants make up the medical therapy component.

Regional Analysis

North America held the biggest market share and contributed USD 16.19 billion of every 2021 attributable to created medical care foundation, research awards for delivering protected and powerful thrombus treatment, and the developing matured and large populace in the region.

Europe's thrombus treatment market represents the second-biggest market share attributable to the developing examination and treatment of profound vein apoplexy and developing mindfulness with respect to thrombus difficulties are the central point driving the market development in Europe. For example, as per the article distributed in Public Community for Biotechnology Data (NCBI), profound vein apoplexy (DVT) is a medical services trouble in Europe.

The Asia-Pacific thrombus treatment market is supposed to develop at a critical share from2018 to 2030. Attributable to the presence of an enhanced patient pool, the rising pervasiveness of profound vein apoplexy, and expanding mindfulness about the treatment and utilization of medications to treat different apoplexy occasions in nations, for example, China and India are probably going to support the market in the Asia-Pacific region. In addition, China market of thrombus treatment held the biggest market share, and the India market of thrombus treatment is the quickest developing market in the Asia-Pacific region.

Major Players

Key companies in the Thrombus Treatment Market includes Teva Pharmaceutical Industries Ltd. (Israel), AngioDynamics Inc. (US), Bristol-Myers Squibb Company (US), Pfizer Inc. (US), Johnson & Johnson Services Inc. (US), Sanofi S.A. (France), Daiichi Sankyo Company, Limited (Tokyo), Boehringer Ingelheim International GmbH (Germany), Aspen Pharmacare Holdings Limited (US), and Bayer AG (Germany).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW
4.2 DRIVERS
- 4.2.1 INCREASING INCIDENCE OF TRAUMA CASES
- 4.2.2 RISING ADOPTION OF SEDENTARY LIFESTYLE
4.3 RESTRAINTS
- 4.3.1 RISKS ASSOCIATED WITH THROMBOSIS DRUGS
4.4 OPPORTUNITIES
- 4.4.1 NEW PRODUCT APPROVALS AND LAUNCHES

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION AND SALES
- 5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL THROMBUS TREATMENT MARKET
- 5.3.1 IMPACT ON SUPPLY CHAIN
- 5.3.2 IMPACT ON PRODUCTION
- 5.3.3 DEMAND-SUPPLY GAP ANALYSIS
- 5.3.4 IMPACT ON PRICING
5.4 NUMBER OF PROCEDURES FOR PULMONARY EMBOLISM

6 GLOBAL THROMBUS TREATMENT MARKET, BY TYPE

6.1 OVERVIEW
6.2 ATRIAL THROMBUS
6.3 VENOUS THROMBUS

7 GLOBAL THROMBUS TREATMENT MARKET, BY TREATMENT

7.1 OVERVIEW
7.2 MEDICAL THERAPY
7.3 SURGERY
7.4 OTHERS

8 GLOBAL THROMBUS TREATMENT MARKET, BY REGION

8.1 OVERVIEW
- 8.1.1 NORTH AMERICA
  - 8.1.1.1 US
  - 8.1.1.2 CANADA
- 8.1.2 EUROPE
  - 8.1.2.1 GERMANY
  - 8.1.2.2 UK
  - 8.1.2.3 FRANCE
  - 8.1.2.4 ITALY
  - 8.1.2.5 SPAIN
  - 8.1.2.6 REST OF EUROPE
- 8.1.3 ASIA-PACIFIC
  - 8.1.3.1 JAPAN
  - 8.1.3.2 CHINA
  - 8.1.3.3 INDIA
  - 8.1.3.4 AUSTRALIA
  - 8.1.3.5 SOUTH KOREA
  - 8.1.3.6 REST OF ASIA-PACIFIC
- 8.1.4 REST OF THE WORLD
  - 8.1.4.1 MIDDLE EAST
  - 8.1.4.2 AFRICA
  - 8.1.4.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW
9.2 COMPETITIVE BENCHMARKING
9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL THROMBUS TREATMENT MARKET
9.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL THROMBUS TREATMENT MARKET
9.5 KEY DEVELOPMENT ANALYSIS
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 9.6.1 PRODUCT APPROVALS/PRODUCT LAUNCHES
- 9.6.2 PARTNERSHIP/COLLABORATION
9.7 MAJOR PLAYERS FINANCIAL MATRIX
- 9.7.1 SALES (USD MILLION), 2021
- 9.7.2 R&D (USD MILLION), 2021

10 COMPANY PROFILES

10.1 TEVA PHARMACEUTICAL INDUSTRIES LTD.
- 10.1.1 COMPANY OVERVIEW
- 10.1.2 FINANCIAL ANALYSIS
- 10.1.3 PRODUCTS OFFERED
- 10.1.4 KEY DEVELOPMENTS
- 10.1.5 SWOT ANALYSIS
- 10.1.6 KEY STRATEGIES
10.2 SANOFI
- 10.2.1 COMPANY OVERVIEW
- 10.2.2 FINANCIAL OVERVIEW
- 10.2.3 PRODUCTS OFFERED
- 10.2.4 KEY DEVELOPMENTS
- 10.2.5 SWOT ANALYSIS
- 10.2.6 KEY STRATEGIES
10.3 PFIZER INC.
- 10.3.1 COMPANY OVERVIEW
- 10.3.2 FINANCIAL OVERVIEW
- 10.3.3 PRODUCTS OFFERED
- 10.3.4 KEY DEVELOPMENTS
- 10.3.5 SWOT ANALYSIS
- 10.3.6 KEY STRATEGIES
10.4 BAYER AG
- 10.4.1 COMPANY OVERVIEW
- 10.4.2 FINANCIAL OVERVIEW
- 10.4.3 PRODUCTS OFFERED
- 10.4.4 KEY DEVELOPMENTS
- 10.4.5 KEY STRATEGIES
10.5 ANGIODYNAMICS.
- 10.5.1 COMPANY OVERVIEW
- 10.5.2 FINANCIAL OVERVIEW
- 10.5.3 PRODUCTS OFFERED
- 10.5.4 KEY DEVELOPMENTS
- 10.5.5 KEY STRATEGIES
10.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
- 10.6.1 COMPANY OVERVIEW
- 10.6.2 FINANCIAL OVERVIEW
- 10.6.3 PRODUCTS OFFERED
- 10.6.4 KEY DEVELOPMENTS
- 10.6.5 SWOT ANALYSIS
- 10.6.6 KEY STRATEGIES
10.7 BRISTOL-MYERS SQUIBB COMPANY
- 10.7.1 COMPANY OVERVIEW
- 10.7.2 FINANCIAL OVERVIEW
- 10.7.3 PRODUCTS OFFERED
- 10.7.4 KEY DEVELOPMENTS
- 10.7.5 KEY STRATEGIES
10.8 ASPEN HOLDINGS
- 10.8.1 COMPANY OVERVIEW
- 10.8.2 FINANCIAL OVERVIEW
- 10.8.3 PRODUCTS OFFERED
- 10.8.4 KEY DEVELOPMENTS
- 10.8.5 KEY STRATEGIES
10.9 JOHNSON & JOHNSON SERVICES, INC.
- 10.9.1 COMPANY OVERVIEW
- 10.9.2 FINANCIAL OVERVIEW
- 10.9.3 PRODUCTS OFFERED
- 10.9.4 KEY DEVELOPMENTS
- 10.9.5 SWOT ANALYSIS
- 10.9.6 KEY STRATEGIES
10.10 DAIICHI SANKYO COMPANY, LIMITED
- 10.10.1 COMPANY OVERVIEW
- 10.10.2 FINANCIAL OVERVIEW
- 10.10.3 PRODUCTS OFFERED
- 10.10.4 KEY DEVELOPMENTS
- 10.10.5 KEY STRATEGIES

11 APPENDIX

11.1 REFERENCES
11.2 RELATED REPORTS